Table 3.

Multiple regression analysis on outcomes after MAC AlloHCT (A) and after RIC AlloHCT (B).

		DFS		Relapse		NRM		OS
Factor	N	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P
FC+
No	65	1.0		1.0		1.0		1.0
Yes	15	1.1 (0.5–2.5)	0.79	1.3 (0.4–4.1)	0.60	0.6 (0.2–1.9)	0.42	1.1 (0.5–2.4)	0.85
Age
<18	30	1.0		1.0		1.0		1.0
18–35	21	1.5 (0.7–3.5)	0.31	0.3 (0.1–1.6)	0.17	2.4 (0.9–6.9)	0.10	1.5 (0.7–3.5)	0.31
>35	29	2.0 (0.9–4.4)	0.08	1.0 (0.4–2.9)	0.98	2.2 (0.7–6.2)	0.19	2.0 (0.9–4.5)	0.09
Donor Type
Matched Sibling	26	1.0		1.0		1.0		1.0
UCB	54	1.8 (0.8–3.7)	0.07	0.4 (0.2–1.1)	0.09	4.4 (1.3–14.1)	0.01	2.0 (0.9–4.2)	0.08

		DFS		Relapse		NRM		OS
Factor	N	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P
FC+
No	113	1.0		1.0		1.0		1.0
Yes	10	2.9 (1.4–5.9)	<0.01	3.8 (1.7–8.7)	<0.01	0.7 (0.2–2.8)	0.59	3.4 (1.7–7.0)	<0.01
HCT-CI
Low risk	41	1.0		1.0		1.0		1.0
Int. risk	34	1.1 (0.6–2.0)	0.79	0.9 (0.4–1.8)	0.76	1.3 (0.4–4.9)	0.71	1.1 (0.6–2.2)	0.73
High risk	48	1.3 (0.7–2.2)	0.37	0.7 (0.4–1.8)	0.25	3.2 (1.1–8.9)	0.03	1.7 (0.9–3.0)	0.08
CMV Serostatus
Negative	42	1.0		1.0		1.0		1.0
Positive	81	0.9 (0.5–1.4)	0.57	0.4 (0.2–0.8)	<0.01	4.2 (1.3–13)	0.02	1.0 (0.6–1.7)	0.90